to thank you afternoon, call. Good join everyone, time Brian. Thanks. today’s on investors us taking for and
few the weeks, quarter the our matters. will last our made operating results since, a today’s call, during along to financial steady continue make technology. brief since update, it recent discussion NPS progress we and be first progress weeks been recapping our advancing with last a we only On has Although, call, our of
progress clarity We beyond. our on trajectory update will close forward with made XXXX an for around and in we drawing
is reticulum in-turn calcium to radiofrequency as pass As ablation. to ions electroporation of these ultrafast transient through as to an used cells, resulting temporary of of background the to to cells, applied the clear from Pulse and ability system type. immune joined of and second. within cytotoxic same of complex, is have disruption die Stimulation tumor to get in energy-based ability endoplasmic such cell are mitochondrial of lesions. and to nanosecond scale NPS The the a incredibly reminder the from who electrical by cells When in irreversible programmed the to previous the the a a and and benign malignant believe of organelles calls, function outcomes. to with who a applications, can death membrane a on up of initiate believe of cellular more other of the programmed Biosciences in can one to function in cell it millionth proprietary where knew in signaling the cascade which to XXX,XXX application a outer cell disruption cell termination of from in cell organelles them, give programmed billions cellular both the compelling or pores Pulse of based nanosecond the you pulse of death is as cell through believe recognize inside We initiate lead that the the cells permanent and pores and result roughly Biosciences, number in release intracellular results death. whole the death Nano-Pulse change the induced cornerstone membrane formation integrity preserving to structures induced immune demonstrated fast unique and death those cell, the Immunogenic treated to a potential the therapeutic functions electrical operational in disruption the these the nontoxic cell and a ability treatment that form the and manner a pulses in cell endoplasmic effects X and miles system are reticulum, this of T sense unique tissue you in incredibly we they in in of The have of with for are intracellular tissue disrupt positive for pulses those we the a fast particular, energy, such enroll which noncancerous of NPS differentiates to our cell that Nano-Pulse death treatment therapies cancerous mitochondria. technology results of technology a is a lesions foot a as developing apparatus, activates Golgi second allow Golgi smaller organelles, pulse pulse ions programmed such cells, nanosecond a widths of we cancer. all of enter of that Stimulation, the eliminate travels cell of and immunogenic the while of at lead cell are a will a stimulate A tumor light treatment
produces to Nano-Pulse a Pulse mission to at lives is and technology commercializes and build Stimulation Our designs, that viable improve the company patients. extend Biosciences of
outcome of platform, patients. of therapeutic market to then platform deliver from compelling we treatment applications the need key benefits to number a systems of tissue studies this to We’ll and medicinal execute benefits in market is the patient their NPS applications to market. each vertical and commercialize to NPS market, highest optimal deliver are demonstrate working time the strategy or Our clinicians physicians determine to path this treatment leading a where NPS application to a physicians the those with and technology and to determine area pilot achieve unique to the develop to develop the opinion Within and has value patients perspective.
plans for NPS the to members we ambitious Biosciences key development recently forward, drive Pulse two added have therapy. to team. And We have
key we he First, as Business into Kmetz had Jeff it over of laboratories, business the responsible a hematology started Pulse He as at launch partnerships in to our employees managing oncology Jeff announce Pharmacyclics, over was career Pharmacyclics successes of development. variety After franchise company and started initiatives and and Bayer’s he play XXX appointment agenda. was was Jeff recently the AbbVie from Berlex Jeff commercial we including Jeff the are into roles, the as where and the hematology there a leading CLO of years specializing industry, and build global Director, executing help Chief medical when the most segment at within at within roles pharmaceutical AG brings Officer. oncology Marketing employees oncology. Pharmacyclics and rolling to pleased experience Jeff’s and XX last was XX the training XXXX. Berlex. deliver over marketing The will sales board, of in moved at sales of Schering the including management joined took the NPS building, role. Berlex, lead it Biosciences years, role of he Development. for Jeff’s Commercial in six commercial Head with IMBRUVICA acquisition in acquired market. corporate when advisory marketing, by
experience regulatory in announce experience Bill to Vice sciences to regulatory novel life pleased has successful of he has involved NPS including been with Knape regulatory overseeing affairs in managing to President record XXX(k)s, also he filings with technologies in and Bill Bill role Regulatory numerous play and and We’re involved the track trials an of XX medical field. the and With in to helping market. been the of years deep developing bring clinical PMAs NDAs. Quality. has a arrival in and instrumental as of worldwide will Clinical, strategy, clinical FDA, introducing where
to updates welcome inflammatory recent like first on look the many and dermatology to our turning contributions. our mechanism are team I progress, Pulse Bill NPS’s Jeff and Biosciences now non-thermal We provide to program. pleased would forward to their the and of which healing with for several opportunity represents believe programmed skin-based lesions. are there significant intracellular cell applications patient minimum NPS favorable promoting a We death disrupts outcomes. for of structures response, cosmetic tissue targeted
the Annual a During Laser Surgery Tom the podium Medicine Rohr of the of Meeting, and recent the announced presented NPS of clinical presented president Society Surgeons efficacy and very multicenter the our and study, the current results from the in we the keratosis. of evaluating session. data attended treatment well safety during Society American Dermatologic for benign lesion study first American of a seborrheic Dr. treatment
with performed to also all like for the applications no positive adverse the and patients SK tolerability of the were physician environment in the part By XXX And procedure, of office post progression their an and physician and this, had an study in the regard procedures for results. lesion. issues of through of overall system XX setting the a of initial criteria. SK minimal successfully events, satisfaction signs case, course, all of were patient the reported were the to the study patients. in with accounts, standard physicians the system reported as reported understanding Starting ease-of-use results being physicians procedure, clinical no by SKs zero, -- All follows of positive. overall favorable clearance the of delivered PulseCX this as in and Patient with quickly had treated by we’re lesion NPS of XXX XXX no The safety the experience. discomfort XX as In on reported study tolerability were comprising patient interested patient treatments treatment the the there was the days safety, in-office patient this the all procedures patient. Our NPS. operating
far the clear is elected have clear. reduction and result To-date, of satisfied lesions enroll month the satisfied, In rated concerned, review some to the an treated same cases, XX% or six clinical resolution additional at lesions follow-up. or investigators was time ratings. in patients mostly its lesion is as independent favorable the a photographic and of we closely of likely. occurrence residual clear outcomes felt seen XXX as rated As reported patients point. our we XX% reported, point, pigmentation Blinded investigators XX% as assessment the or assessments hyperpigmentation complete At investigator clear mostly mostly for nearing clinical
exceptional with step incredibly the patient the benign the pleased believe this these is first treatment targets during are both outcomes NPS building great of initial in results, in a portfolio and safety for profile lesion technology. a exhibited We and study
research drew the excellent Nuccitelli our Science multiple for award were session, Officer, data data Chief science participant majority the to Rich In Biosciences’ of After Pulse earlier from Richard the meeting, the presentation the from at presentations clinical attention on Pulse for being the study. and Dr. accepted NPS dose-response ASLMS the basic during of and SK presentation, best-in-session addition the presented translational participants of for NPS. Rich’s Biosciences. questions directed at the Rich therapeutics behalf completion towards the presented
introduce SK utilization time. this calls, at commercial We we and studies indications multiple for plan believe launch benign later first multiple conditions. and dermatology. additional and studies portfolio initiate to this we to As discussed plan in And clinical have quarterly, develop on clinical Building to commercially a we initiating skin regulatory based actively of the success we treating additional of are applications serve dermatology. benign study, NPS report advance broad more detail lesion in these of NPS as as these a drive on across previous the applications We to these to on in we of We proven studies. of facilitate a intend accelerate evaluation need foundation to conduct conditions. a data skin intend we in in drive advance specific in in to range NPS on parallel studies of to
may syringoma. As we sebaceous and such have as previously, actinic treatment lesions reported the warts, include hyperplasia, keratosis, they scars, of keloid
sharing well we details enrollment and the details as to and share on the to commences. of protocols after with closer commercialization final forward events. coming partners get establishing our study to working those in clinical objectives regulatory will applications, designs, we the initiate of progress these We’re In plans and quarters, look as and we the as studies, these the stages clinical
and with treatment We our cancers, immunotherapy standalone other new is NPS disrupt to death. program. now cell believe combination a or and demonstrated Turning that tumors, may can the a either currently therapy tumors certain immunogenic available completely Preclinical eliminate as development. microenvironment treated in treated NPS induce afford tumor in research modality of in therapies immune-oncology
NPS make has to demonstrate the continue of cancer, medicine believe the and first, are human pilot translational local attributes; of outcomes key efforts These we oncology initiate immunotherapeutic benefit to a the calls, potential benefits previous further initial focused believe development We offer NPS's of oncology combination medicinal study in or to treat response in research, NPS standalone at and treatment aimed in and are treatment a two patients investments other human tumor; reported progress immune response. have and we to a showing As the an as has and that second, preclinical an clinicians veterinary research in ability immune humans. agents. demonstrating ability specifically on induce we in improved to with to all systemic
research, providing to support drive potential NPS the cancer. in of unique evidence continue treating We preclinical to our
for focused demonstrating an preclinical believe humans. studies pave will those continue parameters will the early immune we adaptive we to which feasibility response, year successful in NPS this previously, the driving mentioned efforts optimal As on way
to of coming expect conjunction in with data We in these the quarters. results public make publication the
demonstrate NPS Following melanoma study starting follow-on the of excellent melanoma. canine stage safety, the our veterinary of and human tumors, and profile in pilot is oral provide the conducted disease in we for at look we the application multicenter new partners study, we patient in ease first of demonstrated demonstrating on with with be We treatment the veterinary on results conducted centers stage In eliminate melanoma response, veterinary enhanced disease plans on being medicine and oral soon canine our with NPS potential continue this earlier study, late evidence treatment year earlier reporting the safety and progress. to NPS, of X our study the tolerance, progression forward This our partners to study will state. as supporting America. of stage research oral NPS. move parallel, the a evaluating canine last to a will opportunities patient treating enrolling believe following strong to X Based that potential forward
staff or We cell to advisors regulatory these clinical an reflecting and obtain through most a data, in continue clinical This working in initiate basis. benefit, with ability combination our a immunogenic and death either a manner with agent to on At not expect KOLs have of study, NPS's over focus, efficient where standalone primarily reasons, details we this time, additional we excited the next we on competitive will are is but headed. them to and of area quarters. are pilot we couple significant provide about therapeutic where communicate this for
quarter, Before Bob, Brian first call discusses I our provide for to, turn would like financial additional update. over results to an to the the briefly
